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Introduction: Prostacyclin is an important cardioprotective hormone produced by the 
vascular wall, whose synthesis is dependent on cyclo-oxygenase (COX) enzymes. In healthy 
vessels the endothelium is thought to be the main site of prostacyclin release (Moncada et al 
1977). Two isoforms of COX exist, and we have recently published data demonstrating that it 
is COX-1 rather than COX-2 that drives the production of prostacyclin in mouse aorta 
(Kirkby et al 2012).  In this study we aimed to extend these observations by investigating 
what proportion of the COX-1 driven aortic prostacyclin production that comes from the 
endothelium versus the rest of the vessel wall (smooth muscle layers and adventitia). To do 
this, we explored how removal of the endothelium would influence the ability of aortic tissue 
to release prostacyclin in response to a range of agonists that are known to activate the 
endothelium and the vessel wall. 
Methods: Wild type (WT, C57BL/6 mice) and COX-1-/- mice (n=4, 10-12 weeks old) were 
killed by CO2 induced asphyxiation. Aortas were removed and divided into 2mm rings after 
which in some rings the endothelium was removed by rubbing of the luminal surface with 
forceps. Aortas were allowed to equilibrate in Dulbecco’s modified eagle’s medium (DMEM) 
for 60 mins at 37°C, before medium was replaced and vessels incubated with A23187 
(50µM), bradykinin (100nM), thrombin (1U/ml), ADP (10µM), acetylcholine (ACh, 10µM), 
or vehicle (0.1% DMSO). After 30 mins, medium was removed for measurement of the stable 
prostacyclin breakdown product, 6-keto-PGF1α, by enzyme immunoassay. 
Results: The release of prostacyclin from COX-1-/- vessels was substantially less (<10%) than 
that from WT vessels, both under control conditions and in the presence of blood vessel 
agonists (Table 1). As the levels of prostacyclin production recorded from intact COX-1-/- 
vessels were towards the limit of detection of our immunoassay it cannot be reliably reported 
if these were decreased by endothelial cell removal (Table 1).  In WT vessels the production 
of prostacyclin to ACh following removal of the endothelium was reduced by 69±11%; the 
productions to other agonists were not significantly changed (Table 1). 
Table 1 
Genoty
pe 
+/- 
endotheli
um vehicle A23187 ACh ADP 
bradyki
nin thrombin 
+ 
202 ± 
39 
6382 ±  
2329 * 
1500 ± 
690 
216 ± 
57 
780 ± 
489 955 ± 407 
WT 
- 
318 ± 
19 
3000 ±  
1399 
308 ± 
78 
481± 
191 
478 ± 
90 690 ± 331 
+ 16 ±1  121 ±17  25 ± 3 17 ±2  18 ± 2 14 ± 1 COX-1-
/-
 
- 15 ±2  107 ±4 12 ± 2  12 ± 1  16 ±3  12 ± 1 
Data is mean ± S.E.M for tissue from n=4 mice. *; p<0.05 vs. vehicle by two-way ANOVA. 
Summary: 
This data reiterates the overwhelming role of COX-1 in the production of prostacyclin by 
healthy blood vessels, regardless of the agonist used. It also suggests that the production of 
prostacyclin in normal vessels is dependent upon both endothelial and non-endothelial cells, 
but that the relative roles of these sources vary with different agonists. 
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